Cancer prevention by bovine lactoferrin: from animal studies to human trial.
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers and, despite improved colonoscopic screening, CRC is a leading cause of death from cancer. Administration of bovine lactoferrin (bLF) suppresses carcinogenesis in the colon and other organs of test animals, and recently it was shown that ingestion of bLF inhibits the growth of adenomatous polyps in human patients. Here we review work which established bLF as an anti-carcinogenic agent in laboratory animals and the results of a clinical trial which demonstrated that bLF can reduce the risk of colon carcinogenesis in humans.
Tsuda
Hiroyuki
H
Nanotoxicology Project, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Kozu
Takahiro
T
Iinuma
Gen
G
Ohashi
Yasuo
Y
Saito
Yutaka
Y
Saito
Daizo
D
Akasu
Takayuki
T
Alexander
David B
DB
Futakuchi
Mitsuru
M
Fukamachi
Katsumi
K
Xu
Jiegou
J
Kakizoe
Tadao
T
Iigo
Masaaki
M
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002417:Cattle; D015179:Colorectal Neoplasms / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007781:Lactoferrin / Q000494:pharmacology*
D016588:Anticarcinogenic Agents; D007781:Lactoferrin